Please ensure Javascript is enabled for purposes of website accessibility

Why Inovio Pharmaceuticals Stock Is Bouncing Back Today

By Keith Speights – Jul 2, 2020 at 11:14AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors seem to think a 37% drop this week presents a good opportunity to buy the biotech stock.

What happened

Shares of Inovio Pharmaceuticals (INO 3.61%) were bouncing back on Thursday after being clobbered earlier this week. The stock was up 8.5% as of 11:05 a.m. EDT. 

Inovio didn't report any new developments. However, it appears that investors believe the sell-off was overdone following the company's announcement on Tuesday of interim results from an early stage clinical study of COVID-19 vaccine candidate INO-4800.

Healthcare professional holding a syringe and vial.

Image source: Getty Images.

So what

The biotech stock still has a long way to go to make up its lost ground. Inovio's shares were down 37% this week as of the close on Wednesday.

Investors reacted negatively to Inovio's lack of details in its interim results for INO-4800. The company said that 94% of participants "demonstrated overall immune responses" after receiving two doses of the experimental vaccine. However, Inovio didn't reveal how many patients had neutralizing antibodies that could prevent infection.

Inovio will provide more details from its phase 1 study of INO-4800 in the not too distant future, though. If the COVID-19 vaccine advances to a phase 2/3 study, the current suspicions about efficacy problems should largely fade away.

Now what

Investors should get some answers pretty soon. Inovio hopes to initiate the phase 2/3 study of INO-4800 this summer if the FDA gives a green light for the clinical trial. The company also plans to publish the full data from its phase 1 study of the COVID-19 vaccine candidate in a peer-review medical journal. At this point, though, the publication date is uncertain. 

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
$1.72 (3.61%) $0.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.